Clinical Trials

This study is for advanced cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists.

(STUDY IS CLOSED AT THIS SITE) This a phase II clinical trial for patients with advanced papillary kidney cancer (renal cell carcinoma), which compares the use of cabozantinib alone versus cabozantinib in combination with atezolizumab.

This is study is treating low tumor burden follicular lymphoma, a type of slow-growing (indolent) blood cancer with a minimal amount of disease present in the body. The purpose of this study is to compare the usual treatment (rituximab) to using the study drug mosunetuzumab.

(CLOSED at this Site) This study wants to find out if a blood test can help doctors decide which patients need more treatment after surgical removal of the bladder, kidney, ureter, or urethra. This blood test looks for small pieces of cancer DNA, called ctDNA, in the blood. If ctDNA is found, it means some cancer cells may still be in the body. The trial will give some patients an extra medicine, called immunotherapy, to help their immune system find and kill any remaining cancer. This will help doctors learn if using the blood test to guide treatment will help patients live longer without their cancer coming back.

This study tests treatment for people with early-stage breast cancer that has a high chance of coming back after treatment. It will test adding an immunotherapy drug called durvalumab to usual chemotherapy before surgery. To determine if cancer has a high chance of returning, the trial uses a test called MammaPrint. The MammaPrint test predicts how likely it is the cancer will come back (recur) by looking at many genes in cancer cells. Treatment in the trial is for patients who receive a High 2 result on MammaPrint testing.

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

NRG-GI008, also known as the “CIRCULATE-NORTH AMERICA” trial, is a clinical study for people with stage III and high-risk stage II colon cancer. The study will be seeking to determine whether chemotherapy is needed for all or only some patients in this population, and, if chemotherapy is needed, what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA (ctDNA) following surgery for colon cancer. The study aims to both spare patients who may not need chemotherapy from its side effects and, for patients who do need chemotherapy, to better determine the most effective form of chemotherapy for them.

This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.

This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.